---
layout: post
title: "Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal"
date: 2026-02-05 18:55:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-12293
original_published: 2023-06-09 00:00:00 +0000
significance: 8.00
---

# Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 09, 2023 00:00 UTC
**Document Number:** 2023-12293

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2024, expiration date.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/09/2023-12293/advisory-committee-dermatologic-and-ophthalmic-drugs-advisory-committee-renewal)
- API: https://www.federalregister.gov/api/v1/documents/2023-12293

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
